Carmen Criscitiello

Sep 24, 2024 | medscape.com | Sara M. Tolaney |Rupert Bartsch |Carmen Criscitiello

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. In recent years, there have been significant advancements in the treatment of HER2+ metastatic breast cancer (MBC), broadening the array of available therapeutic options. However, navigating the complexities of selecting the optimal sequence for HER2 targeted therapies remains challenging.

Apr 17, 2024 | dailyreporter.esmo.org | Carmen Criscitiello

As oncologists, our perpetual challenge is to be at the forefront of transformative research that redefines patient care. In breast cancer treatment, poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors have been heralded as part of the vanguard of precision medicine, but the population of patients who derive a substantial benefit from these agents is still limited.